Drug Profile


Alternative Names: ASP-2215; ASP2215 hemifumarate; Gilteritinib fumarate

Latest Information Update: 12 Jun 2017

Price : $50

At a glance

  • Originator Astellas Pharma
  • Class Amides; Aniline compounds; Antineoplastics; Piperazines; Piperidines; Pyrans; Pyrazines; Small molecules
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Proto oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase I/II Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 13 Jun 2017 Astellas Pharma plans a phase III trial for Acute myeloid leukaemia (Refractory metastatic disease, Second-line therapy or greater) (NCT03182244)
  • 16 May 2017 Astellas Pharma initiates a phase III trial in Acute myeloid leukaemia (Maintenance therapy) in Japan, Denmark and Spain (NCT02997202; EudraCT2016-001061-83)
  • 01 Mar 2017 Astellas Pharma initiates an expanded access of gilteritinib for Acute myeloid leukaemia (NCT03070093)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top